This webcast features: Hakyung Kim, Senior Scientist, Upstream Process Development & Dongyoung Park, Senior Scientist, Upstream Process Development, Samsung Biologics.
Recent innovations in intensified fed-batch (IFB) processing have dramatically improved cell culture yields and scalability, offering a powerful solution for optimizing biopharmaceutical production. By incorporating the IFB approach, Samsung Biologics has developed a platform that optimizes crucial process parameters to maximize the productivity of cultured cell lines.
Join Samsung Biologics for this webinar as they explore the latest advancements in IFB processing and discuss how our novel platform, S-Tensify™, ensures consistent quality and productivity in an increasingly complex production landscape.
Key Takeaways:
Learn how Samsung Biologics integrated intensified fed-batch (IFB) processing to achieve higher densities of viable cells during the N-1 step.
Discover how Samsung Biologics’ IFB platform, S-Tensify™, optimizes cell culture processes, enhancing yield and material quality.
Explore case studies that demonstrate a 30-fold increase in inoculation cell density using the S-Tensify™ platform.
Register or Login and hit Watch on Demand to view the recorded webcast now.